Bayer's (BAYRY) Phase III Study on Nubeqa Combo Meets Goal :

Bayer's (BAYRY) phase III study evaluating Nubeqa in combination with docetaxel and androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer meets the primary endpoint.

Related Keywords

China , Finland , Japan , , Glaxosmithkline , Precision Biosciences Inc , Endo International , European Union , Zacks Investment Research , Orion Corporation , Zacks Investment , Zacks Rank , Precision Biosciences , Strong Buy , Legal Marijuana Looking , Investment Research , Zack Marijuana Moneymakers , Watch List , Download Marijuana Moneymakers , Stocks , Finance ,